MTOR and neuroendocrine neoplasm: Cross-talk between the PI3K/AKT/mTOR pathway and the MAPK pathway has been described in neuroendocrine neoplasms and other cancer types, and dual inhibition of these pathways has been shown to be more effective in in vitro and in vivo neuroendocrine neoplasm models [34,35,36].